A Framework Born in Rome
In 1988, gastroenterologists gathered in Rome to address a fundamental problem: functional gastrointestinal disorders had no standardised diagnostic criteria. Doctors diagnosed IBS by excluding everything else — a costly, time-consuming process that left patients feeling that their condition was defined only by what it was not. The Rome Working Teams set out to create positive, symptom-based criteria.
Rome I (1994) was the first published classification, establishing criteria for 21 functional GI disorders. It was a milestone, but the criteria were largely opinion-based and lacked validation. Rome II (2000) refined the criteria and introduced time-based thresholds — symptoms needed to be present for at least 12 weeks in the preceding 12 months for IBS. It also expanded coverage and began incorporating the biopsychosocial model.
Rome III (2006) further tightened temporal criteria and improved subclassification. For IBS, it required symptom onset at least 6 months before diagnosis and active symptoms for at least 3 days per month in the preceding 3 months. This was the first iteration to gain widespread clinical adoption and underpinned a generation of clinical trials.
Rome IV (2016) represented the most significant conceptual shift. It rebranded functional GI disorders as "Disorders of Gut-Brain Interaction" (DGBI), explicitly acknowledging the bidirectional gut-brain axis as the central mechanism. It classified 33 adult and 20 paediatric disorders across six anatomical domains. For IBS, it changed "discomfort" to "pain" (removing a subjectively ambiguous term) and increased the frequency threshold to at least 1 day per week — which paradoxically reduced IBS prevalence estimates from roughly 11 percent (Rome III) to about 4 percent (Rome IV) by excluding milder cases.
Strengths
The Rome criteria established functional GI disorders as legitimate medical conditions with defined diagnostic criteria — reducing unnecessary invasive testing, enabling consistent clinical trial enrolment, and facilitating patient-doctor communication. The move from diagnosis of exclusion to positive diagnosis was transformative.
Limitations
Critics argue that the Rome system is overly categorical — dividing continuous spectra of symptoms into discrete boxes. Patients frequently meet criteria for multiple overlapping disorders (IBS plus functional dyspepsia, for instance). The criteria are also culturally Western-centric and may not capture symptom patterns in non-Western populations. The expert consensus process, while rigorous, has been criticised for potential industry influence and for producing criteria that are more useful in research than in clinical practice.
Perhaps the most fundamental criticism is that symptom-based criteria cannot capture the mechanistic heterogeneity within a single diagnosis. Two patients meeting Rome IV IBS-D criteria may have entirely different underlying pathophysiology — one driven by bile acid malabsorption, another by post-infectious visceral hypersensitivity, a third by mast cell activation. Rome V, currently in development, is expected to incorporate biomarkers and multidimensional profiling to address this limitation.